WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317900

CAS#: 93957-54-1

Description: Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class.

Price and Availability

Size Price Shipping out time Quantity
10mg USD 180 2 Weeks
25mg USD 320 2 Weeks
50mg USD 550 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-27. Prices are subject to change without notice.

Fluvastatin, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 317900
Name: Fluvastatin
CAS#: 93957-54-1
Chemical Formula: C24H26FNO4
Exact Mass: 411.1846
Molecular Weight: 411.4659
Elemental Analysis: C, 70.06; H, 6.37; F, 4.62; N, 3.40; O, 15.55

Synonym: Fluvastatin, Lescol, Canef, Vastin, Cranoc, XU-62320

IUPAC/Chemical Name: (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid


InChi Code: InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1

SMILES Code: O=C(O)C[C@H](O)C[C@H](O)/C=C/C(N1C(C)C)=C(C2=CC=C(F)C=C2)C3=C1C=CC=C3

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Janić M, Lunder M, Šabovič M. A low-dose combination of fluvastatin and valsartan: a new "drug" and a new approach for decreasing the arterial age. Biomed Res Int. 2015;2015:235709. doi: 10.1155/2015/235709. Epub 2015 Mar 3. Review. PubMed PMID: 25821790; PubMed Central PMCID: PMC4363554.

2: Voûte MT, Winkel TA, Poldermans D. Safety of fluvastatin in patients undergoing high-risk non-cardiac surgery. Expert Opin Drug Saf. 2010 Sep;9(5):793-800. doi: 10.1517/14740338.2010.499120. Review. PubMed PMID: 20557267.

3: Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet. 2008;47(7):463-74. Review. PubMed PMID: 18563955.

4: Stein EA, Corsini A, Gimpelewicz CR, Bortolini M, Gil M. Fluvastatin treatment is not associated with an increased incidence of cancer. Int J Clin Pract. 2006 Sep;60(9):1028-34. Review. PubMed PMID: 16939542.

5: Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol. 2007 Apr 12;117(1):64-74. Epub 2006 Aug 4. Review. PubMed PMID: 16889855.

6: Chan MY, Lee CH. Fluvastatin: efficacy and safety in reducing cardiac events. Expert Opin Pharmacother. 2005 Sep;6(11):1883-95. Review. PubMed PMID: 16144508.

7: Corsini A, Holdaas H. Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. Ren Fail. 2005;27(3):259-73. Review. PubMed PMID: 15957541.

8: Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP, Wierzbicki AS, Elisaf MS. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin. 2005 Feb;21(2):231-44. Review. PubMed PMID: 15801994.

9: Corsini A. The use of statins in optimising reduction of cardiovascular risk: focus on fluvastatin. Int J Clin Pract. 2004 May;58(5):494-503. Review. PubMed PMID: 15206507.

10: Corsini A, Jacobson TA, Ballantyne CM. Fluvastatin: clinical and safety profile. Drugs. 2004;64(12):1305-23. Review. PubMed PMID: 15200346.

11: Tysk C, Al-Eryani AY, Shawabkeh AA. Acute pancreatitis induced by fluvastatin therapy. J Clin Gastroenterol. 2002 Nov-Dec;35(5):406-8. Review. PubMed PMID: 12394230.

12: Langtry HD, Markham A. Fluvastatin: a review of its use in lipid disorders. Drugs. 1999 Apr;57(4):583-606. Review. Erratum in: Drugs 1999 Sep;58(3):404. PubMed PMID: 10235694.

13: Garnett WR. A review of current clinical findings with fluvastatin. Am J Cardiol. 1996 Sep 26;78(6A):20-5. Review. PubMed PMID: 8875971.

14: Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs. 1996 Mar;51(3):433-59. Review. PubMed PMID: 8882381.

15: Peters TK. Treatment of dyslipidaemias with fluvastatin. Br J Clin Pract Suppl. 1996 Jan;77A:16-9. Review. PubMed PMID: 8729585.

16: Baggio G. [An update on the use of fluvastatin in primary hypercholesterolemia]. Ann Ital Med Int. 1995 Oct;10 Suppl:43S. Review. Italian. PubMed PMID: 8562264.

17: Jokubaitis LA. Updated clinical safety experience with fluvastatin. Am J Cardiol. 1994 May 26;73(14):18D-24D. Review. PubMed PMID: 8198019.

18: Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation. 1993 Apr;87(4 Suppl):III45-53. Review. PubMed PMID: 8462180.

19: McDonald KJ, Jardine AG. The use of fluvastatin in cardiovascular risk management. Expert Opin Pharmacother. 2008 Jun;9(8):1407-14. doi: 10.1517/14656566.9.8.1407 . Review. PubMed PMID: 18473714.

20: Asberg A, Holdaas H. Fluvastatin and fluvastatin extended release: a clinical and safety profile. Expert Rev Cardiovasc Ther. 2004 Sep;2(5):641-52. Review. PubMed PMID: 15350166.